Trial Profile
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma With Preserved Liver Function. HCRN: GI15-225
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 17 Oct 2019
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 14 Oct 2019 Planned End Date changed from 1 Jan 2020 to 1 Jan 2021.
- 14 Oct 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2020.
- 01 Apr 2019 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.